肿瘤细胞治疗研究
英文原题：GPC-3 in hepatocellular carcinoma; A novel biomarker and molecular target.
肝细胞癌（HCC）因诊断晚和复发率高而成为全球健康问题。
肝细胞癌（HCC）因诊断较晚且复发率高，已成为全球性健康问题。利用特异且敏感的生物标志物实现HCC早期发现和诊断，并采用新型治疗方法改善患者结局，至关重要。磷脂酰肌醇蛋白聚糖3（GPC-3）是一种细胞表面蛋白聚糖，在包括HCC在内的多种肿瘤中过表达。GPC-3可作为HCC早期发现的特异性生物标志物，也可能成为精准治疗策略的靶点。有效识别GPC-3有望同时改善HCC诊断和靶向治疗；此外，采用GPC-3靶向治疗可能获得更好的疗效。近年来，GPC-3靶向疗法已用于多种研究性治疗方案，包括双特异性抗体或单克隆抗体、肽疫苗和CAR-T细胞疗法。本研究旨在阐明GPC-3的诊疗一体化潜力：既可作为早期发现的新型生物标志物，也可作为HCC治疗的潜在分子靶点。
Hepatocellular carcinoma (HCC) is a global health issue due to its late diagnosis and high recurrence rate. The early detection and diagnosis of HCC with specific and sensitive biomarkers and using novel treatment approaches to improve patient outcomes are essential. Glypican-3 (GPC-3) is a cell surface proteoglycan that is overexpressed in many tumors, including HCC. GPC-3 could be used as a specific biomarker for HCC early detection and could be a potential target for precise therapeutic strategies. Effective identification of GPC-3 could improve both diagnosis and targeted therapy of HCC. Moreover, targeted therapy using GPC-3 could result in a better treatment outcome. Recently, GPC3-targeted therapies have been used in different investigational therapeutic approaches like bi-specific/monoclonal antibodies, peptide vaccines, and CAR T cell therapies. This study aims to highlight the theranostic potential of GPC-3 as a novel biomarker for early detection and as a potential molecular target for HCC treatment as well.
MEMBER ACCOUNT
登录成功会直接打开下一页。
